Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

NCT07134998 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced KRAS G12D Mutant Solid Tumors

Interventions

DRUG: HRS-6093

Sponsor

Jiangsu HengRui Medicine Co., Ltd.